SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-23-001677
Filing Date
2023-02-14
Accepted
2023-02-14 09:35:53
Documents
1

Document Format Files

Seq Description Document Type Size
1 ACRIVON THERAPEUTICS, INC. p23-0196sc13g.htm SC 13G 48474
  Complete submission text file 0000902664-23-001677.txt   50222
Mailing Address C/O MARSHALL WACE NORTH AMERICA L.P. 350 PARK AVE., 18TH FLOOR NEW YORK NY 10022
Business Address C/O MARSHALL WACE NORTH AMERICA L.P. 350 PARK AVE., 18TH FLOOR NEW YORK NY 10022 212-235-2800
Marshall Wace North America L.P. (Filed by) CIK: 0001325091 (see all company filings)

IRS No.: 470943020 | State of Incorp.: DE | Fiscal Year End: 0930
Type: SC 13G

Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Subject) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-93824 | Film No.: 23623492
SIC: 2834 Pharmaceutical Preparations